Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2/3 × Hematologic Neoplasms × kalinox × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Hematologic Neoplasms 1

Interventions

Stem Cell Transplantation 3 cobimetinib 2 Vemurafenib 2 Cyclophosphamide 2 trametinib 1 thymoglobulin 1 pertuzumab 1 peginterferon alfa-2b 1 orelabrutinib 1 kalinox 1 entrectinib 1 dabrafenib 1 capmatinib 1 atezolizumab 1 alectinib 1 Trimethoprim, Sulfamethoxazole Drug Combination 1 Tretinoin 1 Trastuzumab 1 Standard of Care 1 Practice Guidelines as Topic 1 Patient Comfort 1 Palliative Care 1 Melphalan 1 Immunotherapy, Adoptive 1 Immunoglobulins 1 Imipenem 1 Granulocyte Colony-Stimulating Factor 1 Filgrastim 1 Ferric Oxide, Saccharated 1 Darbepoetin alfa 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03483194 2020-06-23

REVEH

Weprom

Phase 2/3 Completed

Other hematologic neoplasm

Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡